Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

(2017) John D. Norris et al.   JOURNAL OF CLINICAL INVESTIGATION

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer

(2017) Michael A. Gordon et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

(2016) H. Bonnefoi et al.   ANNALS OF ONCOLOGY

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

(2016) W. Li et al.   CLINICAL CANCER RESEARCH

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

(2015) J. O'Shaughnessy et al.   ANNALS OF ONCOLOGY

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer

(2015) Andrew Ciupek et al.   BREAST CANCER RESEARCH AND TREATMENT

The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.

(2015) Johann Sebastian De Bono et al.   JOURNAL OF CLINICAL ONCOLOGY

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

(2014) Stephen W. Rafferty et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Adrenal insufficiency

(2014) Evangelia Charmandari et al.   LANCET

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

(2011) Gerhardt Attard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolated 17,20-Lyase Deficiency due to the Cytochrome b5Mutation W27X

(2010) Renée C. Kok et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Letrozole on Plasma Lipids, Triglycerides, and Estradiol in Postmenopausal Women with Metastatic Breast Cancer

(2010) J. Zidan et al.   ONCOLOGIST

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT